Medifast (MED) News Today

DA Davidson restated an "underperform" rating and issued a $17.50 price objective on shares of Medifast in a report on Monday.

Medifast, Inc. (NYSE:MED - Get Free Report) saw a significant decrease in short interest in June. As of June 30th, there was short interest totalling 2,940,000 shares, a decrease of 15.0% from the June 15th total of 3,460,000 shares. Based on an average trading volume of 580,700 shares, the days-to-cover ratio is currently 5.1 days. Currently, 27.7% of the company's shares are short sold.

Vanguard Group Inc. grew its stake in Medifast, Inc. (NYSE:MED - Free Report) by 7.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,686,957 shares of the specialty retailer's stock after purchasi

First Trust Advisors LP grew its position in shares of Medifast, Inc. (NYSE:MED - Free Report) by 67.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 397,443 shares of the specialty retailer's stock af

Medifast, Inc. (NYSE:MED - Free Report) - Investment analysts at DA Davidson issued their Q2 2024 EPS estimates for Medifast in a research note issued to investors on Thursday, June 6th. DA Davidson analyst L. Weiser forecasts that the specialty retailer will earn $0.40 per share for the quarter.

Medifast, Inc. (NYSE:MED - Free Report) - DA Davidson cut their FY2024 earnings per share (EPS) estimates for shares of Medifast in a report issued on Thursday, June 6th. DA Davidson analyst L. Weiser now expects that the specialty retailer will post earnings per share of $0.70 for the year, down

DA Davidson downgraded Medifast from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $25.00 to $17.50 in a research report on Wednesday.

LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result

Medifast, Inc. (NYSE:MED - Free Report) - Analysts at DA Davidson reduced their FY2024 earnings estimates for shares of Medifast in a note issued to investors on Tuesday, April 30th. DA Davidson analyst L. Weiser now expects that the specialty retailer will earn $0.75 per share for the year, down

DA Davidson lowered their price target on shares of Medifast from $40.00 to $25.00 and set a "neutral" rating for the company in a report on Tuesday.

Medifast (NYSE:MED - Get Free Report) announced its earnings results on Monday. The specialty retailer reported $0.66 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by ($0.12). The firm had revenue of $174.74 million for the quarter, compared to the consensus estimate of $168.90 million. Medifast had a return on equity of 56.06% and a net margin of 9.27%. Medifast's quarterly revenue was down 49.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.67 EPS.

Medifast (NYSE:MED) updated its second quarter 2024 earnings guidance. The company provided EPS guidance of 0.050-0.400 for the period, compared to the consensus estimate of 0.780. The company also issued revenue guidance of $150.0 millionillion-$170.0 millionillion, compared to the consensus estimate of $168.9 millionillion.